Article Text

PDF
Usefulness of nefopam in treating pain of severe uncomplicated renal colics in adults admitted to emergency units: a randomised double-blind controlled trial. The ‘INCoNU’ study
  1. Farès Moustafa,
  2. Jérôme Liotier,
  3. Thierry Mathevon,
  4. Daniel Pic,
  5. Christophe Perrier,
  6. Jeannot Schmidt
  1. Pôle SAMU-SMUR-Urgences, CHU Clermont-ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France
  1. Correspondence to Dr Farès Moustafa, Pôle Urgences, CHU Clermont-ferrand, 58 rue Montalembert, BP 69, F-63003 Clermont-ferrand, France; fmoustafa{at}chu-clermontferrand.fr

Abstract

Background Renal colic pain is a frequent cause of emergency department admissions (1–2% of admissions). It is extremely painful, often requiring intravenous morphine titration. The aim of this study was to estimate the effect of adding nefopam to ketoprofen upon subsequent morphine consumption and the time needed to achieve adequate analgesia in renal colic.

Methods The authors undertook a prospective, monocentric, randomised, double-blind, placebo-controlled, parallel-group study, using an intent-to-treat analysis. Patients admitted to the emergency department for suspected hyperalgesic (evaluated with a visual analogue scale (VAS)) renal colic were enrolled in the study. They were administered an initial treatment of ketoprofen before being randomly assigned to either the placebo or nefopam group.

Results Thirty patients admitted to the emergency department were enrolled in the study. Morphine analgesia was necessary for 10 patients (66.6%) (95% CI 40% to 90%) in the nefopam group and 8 (53.3%) (95% CI 30% to 80%) in the placebo group, with no statistically significant difference found (difference 13.3%, 95% CI −51% to 24%). The time needed to achieve adequate analgesia in the case of morphine titration was 8.3 min (95% CI 4.2 to 12.5) in the nefopam group and 9 min (95% CI 2.7 to 15.3) in the placebo group, with no statistically significant difference (difference 0.7, 95% CI 7.25 to 8.58).

Conclusion This study did not reveal any significant difference between nefopam and placebo. This may be due to lack of statistical power or lack of effectiveness.

Clinical trial registration number http://ClinicalTrials.gov ID number NCT00639574.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by the local ethics committee (CPP Sud Est VI).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.